The Cancer Genome Atlas (TCGA) data illustrate that BRD4 amplification occurs most frequently in HGSOC patients across all represented cancer subtypes (15), which implies that HGSOC patients is potential demographic that will benefit from BRD4 inhibitors. The gene discussed is BRD4; the disease is cancer.